{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:19:53Z","timestamp":1793387993306,"version":"4.5.0"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for diabetes and obesity, exhibit pleiotropic effects\u2014including anti-inflammatory, antioxidant, and neuroprotective properties\u2014that position them as transformative candidates for ocular therapeutics. Ocular diseases such as glaucoma and diabetic retinopathy (DR) are driven by multifactorial pathogenesis. Current therapies often target specific pathways or symptoms, and the potential effect of GLP-1RAs on the eye is still debated. The latest research and trials on the effect of GLP-1RAs in the eye were searched until April 2025, including thorough cellular studies, animal studies, and clinical observation surrounding glaucoma, diabetic retinopathy, and other ocular diseases. This review delineates the multifaceted mechanisms by which GLP-1RAs exert ocular benefits, including retinal ganglion cell (RGC) rescue via calcium channel and GABAergic modulation, mitochondrial protection through PINK1\/Parkin-mediated mitophagy and ERK1\/2-HDAC6 signaling, as well as potent anti-inflammatory effects via cytokine reduction and immune cell recruitment inhibition. Moreover, GLP-1RAs contribute to retinal remodeling by stabilizing vascular integrity and extracellular matrix homeostasis, and they display anti-angiogenic properties critical for mitigating neovascular complications. Clinical evidence underscores a reduced incidence of glaucoma and potential benefits in diabetic retinopathy. However, conflicting evidence highlights context-dependent risks, such as early DR worsening in poorly controlled glycemic states. In conclusion, this review synthesizes molecular insights and clinical evidence to underscore GLP-1RAs\u2019 potential as multi-targeted disease-modifying agents, urging further research to translate preclinical promise into safe, effective ocular therapies.<\/jats:p>","DOI":"10.3389\/fphar.2025.1618079","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T05:33:44Z","timestamp":1753335224000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhixuan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianzhe","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ophtha.2025.01.016","article-title":"Glucagon-like Peptide-1 receptor agonist impact on chronic ocular disease including age-related macular degeneration","volume":"132","author":"Allan","year":"2025","journal-title":"Ophthalmology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3390\/ph16081065","article-title":"Neuroprotective impact of linagliptin against cadmium-induced cognitive impairment and neuropathological aberrations: targeting SIRT1\/Nrf2 axis, apoptosis, and autophagy","volume":"16","author":"Arab","year":"2023","journal-title":"Pharm. (Basel)."},{"key":"B3","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson\u2019s disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov. Today"},{"key":"B4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2337\/dc19-1065","article-title":"Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial","volume":"43","author":"Bethel","year":"2020","journal-title":"Diabetes Care"},{"key":"B5","doi-asserted-by":"publisher","first-page":"101261","DOI":"10.1016\/j.preteyeres.2024.101261","article-title":"Addressing neurodegeneration in glaucoma: mechanisms, challenges, and treatments","volume":"100","author":"Bou Ghanem","year":"2024","journal-title":"Prog. Retin Eye Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s13311-021-01018-5","article-title":"Neuroprotection of Exendin-4 by enhanced autophagy in a parkinsonian rat model of \u03b1-Synucleinopathy","volume":"18","author":"Bu","year":"2021","journal-title":"Neurotherapeutics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4093\/dmj.2023.0277","article-title":"Glucagon-like Peptide-1: new regulator in lipid metabolism","volume":"48","author":"Bu","year":"2024","journal-title":"Diabetes Metab. J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.7150\/ijms.20962","article-title":"GLP-1 treatment improves diabetic retinopathy by alleviating autophagy through GLP-1R-ERK1\/2-HDAC6 signaling pathway","volume":"14","author":"Cai","year":"2017","journal-title":"Int. J. Med. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"13100","DOI":"10.3390\/ijms241713100","article-title":"Glucagon-like Peptide-1 receptor activation reduces pulmonary vein arrhythmogenesis and regulates calcium homeostasis","volume":"24","author":"Chan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20071584","article-title":"Dulaglutide modulates the development of tissue-infiltrating Th1\/Th17 cells and the pathogenicity of encephalitogenic Th1 cells in the central nervous system","volume":"20","author":"Chiou","year":"2019","journal-title":"Int. J. Mol. Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ophtha.2024.10.030","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy: a multinational population-based study","volume":"132","author":"Chou","year":"2025","journal-title":"Ophthalmology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/obr.12839","article-title":"Semaglutide as a promising antiobesity drug","volume":"20","author":"Christou","year":"2019","journal-title":"Obes. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7150\/ijms.90273","article-title":"Prescription of glucagon-like peptide 1 agonists and risk of subsequent open-angle glaucoma in individuals with type 2 diabetes mellitus","volume":"21","author":"Chuang","year":"2024","journal-title":"Int. J. Med. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol. Metab."},{"key":"B14","doi-asserted-by":"publisher","first-page":"8961","DOI":"10.1038\/s41598-018-27121-w","article-title":"Dual therapy with liraglutide and ghrelin promotes brain and peripheral energy metabolism in the R6\/2 mouse model of Huntington\u2019s disease","volume":"8","author":"Duarte","year":"2018","journal-title":"Sci. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s13105-022-00939-9","article-title":"Liraglutide provides cardioprotection through the recovery of mitochondrial dysfunction and oxidative stress in aging hearts","volume":"79","author":"Durak","year":"2023","journal-title":"J. Physiol. Biochem."},{"key":"B16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2337\/diabetes.48.1.86","article-title":"Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39","volume":"48","author":"Edwards","year":"1999","journal-title":"Diabetes"},{"key":"B17","doi-asserted-by":"publisher","first-page":"7956","DOI":"10.7150\/thno.45192","article-title":"Targeting the Notch and TGF-\u03b2 signaling pathways to prevent retinal fibrosis in vitro and in vivo","volume":"10","author":"Fan","year":"2020","journal-title":"Theranostics"},{"key":"B68","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.exer.2014.05.004","article-title":"Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats","volume":"127","author":"Fan","year":"2014","journal-title":"Exp. Eye Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.3390\/healthcare11202749","article-title":"The utilization of glucagon-like peptide 1 agonists and risk of following external eye diseases in type 2 diabetes mellitus individuals: a population-based study","volume":"11","author":"Fan","year":"2023","journal-title":"Healthc. (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"eaay8071","DOI":"10.1126\/scitranslmed.aay8071","article-title":"GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats","volume":"12","author":"Fortin","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.7150\/thno.86831","article-title":"Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists","volume":"13","author":"Ghosh","year":"2023","journal-title":"Theranostics"},{"key":"B21","doi-asserted-by":"publisher","first-page":"108624","DOI":"10.1016\/j.exer.2021.108624","article-title":"Geniposide alleviates choroidal neovascularization by downregulating HB-EGF release from RPE cells by downregulating the miR-145-5p\/NF-\u03baB axis","volume":"208","author":"Gu","year":"2021","journal-title":"Exp. Eye Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"107776","DOI":"10.1016\/j.celrep.2020.107776","article-title":"Neurotoxic reactive astrocytes drive neuronal death after retinal injury","volume":"31","author":"Guttenplan","year":"2020","journal-title":"Cell Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ajo.2024.08.030","article-title":"Association between glucagon-like Peptide-1 receptor agonists exposure and intraocular pressure change: GLP-1 receptor agonists and intraocular pressure change","volume":"269","author":"Hallaj","year":"2024","journal-title":"Am. J. Ophthalmol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1080\/21655979.2022.2031418","article-title":"Novel glucagon-like peptide-1 analogue exhibits potency-driven G-protein biased agonism with promising effects on diabetes and diabetic dry eye syndrome","volume":"13","author":"Hao","year":"2022","journal-title":"Bioengineered"},{"key":"B24","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1002\/jcp.29204","article-title":"Role of liraglutide in brain repair promotion through Sirt1-mediated mitochondrial improvement in stroke","volume":"235","author":"He","year":"2020","journal-title":"J. Cell Physiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1016\/j.apsb.2024.03.011","article-title":"Glucagon-like peptide-1 receptor agonists rescued diabetic vascular endothelial damage through suppression of aberrant STING signaling","volume":"14","author":"He","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"B27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hern\u00e1ndez","year":"2016","journal-title":"Diabetes"},{"key":"B28","doi-asserted-by":"publisher","first-page":"855779","DOI":"10.3389\/fphar.2022.855779","article-title":"The enantiomer of allopregnanolone prevents pressure-mediated retinal degeneration via autophagy","volume":"13","author":"Ishikawa","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1080\/15548627.2020.1731270","article-title":"The neurosteroid allopregnanolone protects retinal neurons by effects on autophagy and GABRs\/GABA(A) receptors in rat glaucoma models","volume":"17","author":"Ishikawa","year":"2021","journal-title":"Autophagy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1146\/annurev-med-043021-014919","article-title":"New frontiers in obesity treatment: GLP-1 and nascent nutrient-stimulated hormone-based therapeutics","volume":"74","author":"Jastreboff","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(23)01289-8","article-title":"Glaucoma: now and beyond","volume":"402","author":"Jayaram","year":"2023","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.survophthal.2023.07.002","article-title":"GLP-1 receptor agonists and diabetic retinopathy: a meta-analysis of randomized clinical trials","volume":"68","author":"Kapoor","year":"2023","journal-title":"Surv. Ophthalmol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e97554","DOI":"10.1371\/journal.pone.0097554","article-title":"Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism","volume":"9","author":"Krasner","year":"2014","journal-title":"PLoS One"},{"key":"B34","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1156829","DOI":"10.3389\/fncel.2023.1156829","article-title":"Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma","volume":"17","author":"Lawrence","year":"2023","journal-title":"Front. Cell Neurosci."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3094642","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm."},{"key":"B36","doi-asserted-by":"publisher","first-page":"103129","DOI":"10.1016\/j.redox.2024.103129","article-title":"Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction","volume":"72","author":"Li","year":"2024","journal-title":"Redox Biol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","article-title":"Neurotoxic reactive astrocytes are induced by activated microglia","author":"Liddelow","year":"2017","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"P75","DOI":"10.1016\/j.ophtha.2024.12.020","article-title":"Diabetic retinopathy preferred practice pattern\u00ae","volume":"132","author":"Lim","year":"2025","journal-title":"Ophthalmology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"697440","DOI":"10.3389\/fnmol.2021.697440","article-title":"Glucagon-like Peptide-1 receptor agonist ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) neurotoxicity through enhancing mitophagy flux and reducing \u03b1-Synuclein and oxidative stress","volume":"14","author":"Lin","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/nejmoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/s41598-022-05323-7","article-title":"Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis","volume":"12","author":"Meurot","year":"2022","journal-title":"Sci. Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6269","DOI":"10.3390\/jcm13206269","article-title":"The effect of Glucagon-like-Peptide-1 receptor agonists on diabetic retinopathy progression, central subfield thickness, and response to intravitreal injections","volume":"13","author":"Michaeli","year":"2024","journal-title":"J. Clin. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/j.ophtha.2024.11.019","article-title":"Reply","volume":"132","author":"Muayad","year":"2024","journal-title":"Ophthalmology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ophtha.2024.03.004","article-title":"Association between glucagon-like Peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes","volume":"131","author":"Niazi","year":"2024","journal-title":"Ophthalmology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e12268","DOI":"10.1002\/trc2.12268","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"N\u00f8rgaard","year":"2022","journal-title":"Alzheimers Dement. (N Y)."},{"key":"B73","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41366-021-00955-7","article-title":"Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist","volume":"46","author":"Pontes-da-Silva","year":"2022","journal-title":"Int. J. Obes. (Lond)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3390\/ijms21072351","article-title":"Mechanisms behind retinal ganglion cell loss in diabetes and therapeutic approach","volume":"21","author":"Potilinski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1080\/02713683.2020.1737137","article-title":"Liraglutide up-regulation thioredoxin attenuated m\u00fcller cells apoptosis in high glucose by regulating oxidative stress and endoplasmic reticulum stress","volume":"45","author":"Ren","year":"2020","journal-title":"Curr. Eye Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00395-015-0476-7","article-title":"Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix","volume":"110","author":"Robinson","year":"2015","journal-title":"Basic Res. Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3390\/jcm8030339","article-title":"New insights into the mechanisms of action of topical administration of GLP-1 in an experimental model of diabetic retinopathy","volume":"8","author":"Sampedro","year":"2019","journal-title":"J. Clin. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s13311-019-00805-5","article-title":"Vildagliptin attenuates Huntington\u2019s disease through activation of GLP-1 Receptor\/PI3K\/Akt\/BDNF pathway in 3-Nitropropionic acid rat model","volume":"17","author":"Sayed","year":"2020","journal-title":"Neurotherapeutics"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/nm1196-1254","article-title":"Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene","volume":"2","author":"Scrocchi","year":"1996","journal-title":"Nat. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"112013","DOI":"10.1016\/j.mce.2023.112013","article-title":"Liraglutide intervention improves high-glucose-induced reactive gliosis of M\u00fcller cells and ECM dysregulation","volume":"576","author":"Shan","year":"2023","journal-title":"Mol. Cell. Endocrinol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"800","DOI":"10.4103\/NRR.NRR-D-24-00001","article-title":"Topical administration of GLP-1 eyedrops improves retinal ganglion cell function by facilitating presynaptic GABA release in early experimental diabetes","volume":"21","author":"Shao","year":"2024","journal-title":"Neural Regen. Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jama.2020.21899","article-title":"Glaucoma in adults-screening, diagnosis, and management: a review","volume":"325","author":"Stein","year":"2021","journal-title":"Jama"},{"key":"B51","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling","year":"2023","journal-title":"Br. J. Ophthalmol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.ajpath.2024.12.003","article-title":"Characterization and role of glucagon-like peptide 1 receptor in the lacrimal gland: novel insights into diabetic dry eye pathogenesis","volume":"195","author":"Sun","year":"2025","journal-title":"Am. J. Pathol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1002\/mds.29992","article-title":"Glucagon-like Peptide-1 receptor agonists and risk of Parkinson\u2019s disease in patients with type 2 diabetes: a population-based cohort study","volume":"39","author":"Tang","year":"2024","journal-title":"Mov. Disord."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cmet.2020.05.001","article-title":"GLP-1 receptor signaling in astrocytes regulates fatty acid oxidation, mitochondrial integrity, and function","volume":"31","author":"Timper","year":"2020","journal-title":"Cell Metab."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2025.02.011","article-title":"Risk of glaucoma in patients without diabetes using a glucagon-like peptide 1 receptor agonist","author":"Vasu","year":"2025","journal-title":"Ophthalmology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"B76","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/bph.12490","article-title":"Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration","volume":"171","author":"Wang","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"622737","DOI":"10.3389\/fendo.2021.622737","article-title":"Exenatide attenuates obesity-induced mitochondrial dysfunction by activating SIRT1 in renal tubular cells","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B58","doi-asserted-by":"publisher","first-page":"107680","DOI":"10.1016\/j.isci.2023.107680","article-title":"Exendin-4 promotes retinal ganglion cell survival and function by inhibiting calcium channels in experimental diabetes","volume":"26","author":"Wang","year":"2023","journal-title":"iScience"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/1861940","article-title":"GLP-1 RA improves diabetic retinopathy by protecting the blood-retinal barrier through GLP-1R-ROCK-p-MLC signaling pathway","volume":"2022","author":"Wei","year":"2022","journal-title":"J. Diabetes Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.2337\/db14-1577","article-title":"GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R","volume":"64","author":"Yusta","year":"2015","journal-title":"Diabetes"},{"key":"B60","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1111\/bph.15059","article-title":"Exendin\u20104, a GLP\u20101 receptor agonist regulates retinal capillary tone and restores microvascular patency after ischaemia\u2013reperfusion injury","volume":"177","author":"Zhai","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1428817","DOI":"10.1155\/2022\/1428817","article-title":"DA5-CH and semaglutide protect against neurodegeneration and reduce \u03b1-Synuclein levels in the 6-OHDA Parkinson\u2019s disease rat model","volume":"2022","author":"Zhang","year":"2022","journal-title":"Park. Dis."},{"key":"B62","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/JPD-181503","article-title":"Semaglutide is neuroprotective and reduces \u03b1-Synuclein levels in the chronic MPTP mouse model of Parkinson\u2019s disease","volume":"9","author":"Zhang","year":"2019","journal-title":"J. Park. Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12916-023-02753-6","article-title":"Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies","volume":"21","author":"Zheng","year":"2023","journal-title":"BMC Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"589114","DOI":"10.3389\/fphar.2020.589114","article-title":"Neuroprotective role of GLP-1 analog for retinal ganglion cells via PINK1\/Parkin-Mediated mitophagy in diabetic retinopathy","volume":"11","author":"Zhou","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e93382","DOI":"10.1172\/jci.insight.93382","article-title":"Myeloid cell modulation by a GLP-1 receptor agonist regulates retinal angiogenesis in ischemic retinopathy","volume":"6","author":"Zhou","year":"2021","journal-title":"JCI Insight"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1618079\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T05:33:45Z","timestamp":1753335225000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1618079\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":77,"alternative-id":["10.3389\/fphar.2025.1618079"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1618079","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"article-number":"1618079"}}